On Jan. 4, 2002, The Best Pharmaceuticals for Children Act was signed into law, established a process for the study of on-patent and off-patent drugs for use in pediatric populations, addressing collaboration on scientific investigation, clinical study design, weight of evidence, and ethical and labeling issues.